Pfizer’s Hympavzi receives US FDA approval to treat adults and adolescents with haemophilia A or B without inhibitors: New York Monday, October 14, 2024, 18:00 Hrs [IST] Pfizer ...
Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and ...
Sanofi has announced negotiations with Clayton Dubilier & Rice (CD&R), regarding the potential sale of a 50% controlling ...
Pfizer announced on Friday that the U.S. Food and Drug Administration has granted approval for its once-weekly injection ...
Pfizer has announced the approval of HYMPAVZI by the US Food and Drug Administration (FDA) for patients with haemophilia A ...
The once-weekly injectable joins one-shot haemophilia B gene therapy Beqvez (fidanacogene elaparvovec) in Pfizer’s portfolio, ...
The FDA granted the approval of Hympavzi to Pfizer Inc.
Hemophilia A and hemophilia B are genetic bleeding disorders caused by a dysfunction or deficiency of coagulation factor VIII ...
Pfizer Inc. (PFE) announced Friday that the U.S. Food and Drug Administration has approved HYMPAVZI (marstacimab-hncq) for routine ...
The FDA approved Pfizer’s Hympavzi (marstacimab-hncq) to prevent or reduce the frequency of bleeding episodes in patients age ...
The FDA approved marstacimab (Hympavzi) for routine prophylaxis to prevent or reduce bleeding episodes in adults and ...
The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback